Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. (APEN): 4 pipeline candidates · ~20 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.9 months
D/E 2.38 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Apollo Endosurgery, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$58.0M
Quarterly Burn
$10.3M
Runway
19.9 mo
Revenue
$21.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| apollo esg | BLA Filed |
| apollo esg system | — |
| apollo revise | BLA Filed |
| orbera | Approved |
Frequently asked questions
How many drug candidates are in Apollo Endosurgery, Inc.'s pipeline?
Apollo Endosurgery, Inc. (APEN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apollo Endosurgery, Inc.'s lead drug candidate?
Apollo Endosurgery, Inc.'s most advanced tracked candidate is apollo esg (BLA Filed) for Endoscopic sleeve gastroplasty (ESG) for weight loss.
What is Apollo Endosurgery, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apollo Endosurgery, Inc. has approximately 19.9 months of cash runway.
Who is the CEO of Apollo Endosurgery, Inc.?
Since March is the chief executive officer of Apollo Endosurgery, Inc. (APEN).
Get the full picture on Apollo Endosurgery, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.